DICE Therapeutics, Inc. Common Stock
DICE
DICE was delisted on the 8th of August, 2023.
76 hedge funds and large institutions have $637M invested in DICE Therapeutics, Inc. Common Stock in 2022 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 24 increasing their positions, 23 reducing their positions, and 10 closing their positions.
80% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 10
10% more funds holding
Funds holding: 69 → 76 (+7)
4% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 23
20% less capital invested
Capital invested by funds: $799M → $637M (-$162M)
33% less funds holding in top 10
Funds holding in top 10: 6 → 4 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$14.5M |
| 2 |
ACA
Avoro Capital Advisors
New York
|
+$9.15M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
+$7.12M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$7.1M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$6.98M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Suvretta Capital Management
New York
|
-$10.4M |
| 2 |
LGM
Logos Global Management
San Francisco,
California
|
-$4.98M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
-$3.93M |
| 4 |
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University
Redwood City,
California
|
-$3.13M |
| 5 |
VC
Vivo Capital
Palo Alto,
California
|
-$2.91M |
DICE Hedge Fund Activity: Q1 2022 in Review
76 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in DICE Therapeutics, Inc. Common Stock (DICE) for Q1 2022, worth a combined $637M — down 20% from $799M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new DICE positions and 10 closed out — a net gain of 8 holders — while 24 added to existing stakes and 23 trimmed.
The largest buyer was Perceptive Advisors, adding an estimated $14.5M. The largest seller was Suvretta Capital Management, exiting entirely with an estimated $10.4M sold.
- 76 institutional investors held DICE Therapeutics, Inc. Common Stock (DICE) as of Q1 2022, up from 69 in Q4 2021.
- Funds reported $637M of DICE Therapeutics, Inc. Common Stock stock for Q1 2022, down 20% quarter-over-quarter.
- 18 funds opened new DICE Therapeutics, Inc. Common Stock positions in Q1 2022 and 10 closed out, a net change of +8 holders.
- The largest DICE Therapeutics, Inc. Common Stock buyer in Q1 2022 was Perceptive Advisors, an estimated $14.5M added.
- The largest DICE Therapeutics, Inc. Common Stock seller in Q1 2022 was Suvretta Capital Management, an estimated $10.4M sold.
Based on aggregated 13F filings for Q1 2022.